论文部分内容阅读
The crystal structure of the title compound (C27H38N4O7S3, Mr = 626.79) has been determined by single-crystal X-ray diffraction. The crystal is of triclinic, space group Pīwith a = 9.411(1), b = 11.645(2), c = 14.672(2) , a = 91.80(1), b = 95.36(1), g =104.56(1)o, V = 1547.0 3, Z = 2, Dc = 1.346 g/cm3, l = 0.71073 , m(MoKa) = 0.289 mm-1 and F(000) = 664. The structure was refined to R = 0.0406 and wR = 0.1177 for 4103 observed reflections with I > 2s(I). X-ray diffraction analysis reveals that the title compound is a practically distorted tetrahedron and each molecule contains one lattice H2O by hydrogen bond. The antitumor activity of the title compound against HL-60 human leukemia cells has also been studied by MTT method.
The crystal structure of the title compound (C27H38N4O7S3, Mr = 626.79) has been determined by single-crystal X-ray diffraction. The crystal is of triclinic, space group Pīwith a = 9.411 (1), b = 11.645 = 14.672 (2) a = 91.80 (1) b = 95.36 (1) g = 104.56 (1) o V = 1547.0 3 Z = 2 Dc = 1.346 g / cm3 l = 0.71073 m MoKa = 0.289 mm-1 and F (000) = 664. The structure was refined to R = 0.0406 and wR = 0.1177 for 4103 observed reflections with I> 2s (I). X-ray diffraction analysis reveals that the title compound is a practically distorted tetrahedron and each molecule contains one lattice H2O by hydrogen bond. The antitumor activity of the title compound against HL-60 human leukemia cells has also been studied by MTT method.